Vicore Pharma Holding AB (VCRE)
NASDAQ
$9.66−$0.2500 (−2.52%) on the dayAs of the close; data may be delayed.
VCRE price, last 12 months
Key stats
- Previous close
- $9.91
- Open
- $9.67
- Day range
- $9.60 – $9.84
- 52-week range
- $9.50 – $17.80
- Volume
- 5.6K
- Avg volume (20 days)
- 27.4K
- Market cap
- $271.7M
Performance
1W−6.7%
1M−14.9%
3M—
6M—
YTD—
1Y—
Technicals and fundamentals
About Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
- Listed on
- NASDAQ
- Market cap
- $271.7M